Pipeline
Rich Pipeline With Significant Opportunities
| Product | Target | Indications | Preclinical | Ph I | Ph II | Registration Trial | NDA Approval | Trial Region | Rights regions |
|---|---|---|---|---|---|---|---|---|---|
| HQP1351 | BCR-ABL/KIT | Resistant CML | |||||||
| Resistant CML, Ph+All | |||||||||
| GIST | |||||||||
| Ph + ALL | |||||||||
| APG-2575 | Bcl-2 Selective | r/r CLL/SLL |  |
||||||
| r/r CLL/SLL | |
||||||||
| WM | |||||||||
| AML | |||||||||
| MDS | |||||||||
| MM | |||||||||
| T-PLL | |||||||||
| MCL | |||||||||
| ER+/HER2-BC and solid tumors | |||||||||
| APG-115 | MDM2-p53 | Melanoma and Solid Tumors(IO Combo) | |
||||||
| ACC |  |
||||||||
| AML,MDS | |
||||||||
| APG-1387 | IAP/XIAP | Solid tumors(IO Combo) | |
||||||
| PDAC + Chemo | |||||||||
| HBV | |||||||||
| APG-1252 | Bcl-2/Bcl-xL | NSCLC + TKI | |
||||||
| SCLC + Chemo | |||||||||
| NET |
|
||||||||
| APG-2449 | FAK/ALK/ROS1 | NSCLC / Solid tumors | |
||||||
| APG-5918 | EED Selective | Tumors / Hemoglobinopathy |
|
||||||
| APG-265 | PROTACs MDM2 | Tumors |
|
||||||
| UBX1967/1325 | Bcl Family | DME |
|
||||||
POC
POC in progress